Discover trends, market shifts, and competitive outlooks for the oncology biosimilars industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

#What Are the Projected Market Size and Growth Rates for the Oncology Biosimilars Market From 2025 To 2029?#_x000D_

In the past few years, the size of the oncology biosimilars market has seen substantial growth. It is projected to expand from $6.9 billion in 2024 to $8.85 billion in 2025, marking a compound annual growth rate (CAGR) of 28.3%. The growth experienced during the historical period can be credited to factors such as the increasing prevalence of cancer, the expiry of patents on biologic cancer drugs, government backing for biosimilars, escalating investments in the development and production of biosimilars, and the broadening geographic reach of biosimilars._x000D_

_x000D_

The market size of oncology biosimilars is projected to witness accelerated expansion in the upcoming years, escalating to $16.48 billion by 2029 with a compound annual growth rate (CAGR) of 16.8%. The surge in the predicted period can be linked to the broadening portfolio of oncology biosimilars, focus on patient-oriented care, managing healthcare costs, targeted treatment approaches, and an expanding pipeline. Key trends for the forecasted period involve biobetters, combinations of oncology biosimilars, supportive care biosimilars, and real-world evidence._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=2821&type=smp_x000D_

_x000D_

#What Are the Core Market Drivers Propelling Growth in the Oncology Biosimilars Industry?#_x000D_

The launch of fresh oncology biosimilars is being fueled by the termination of patents for biologics applied in cancer treatment. These biologics, which are finite patentable specific medications produced from living organisms, stimulate the immune system to combat cancer cells. Following their expiration, new biosimilars can be established. Though not identical, biosimilars offer comparable efficiency to biologics, but at a lower expense. As per the Center for Biosimilars, by 2023 around 20 oncology biologic patents will lapse, paving the way for the creation of new biosimilars dedicated to cancer treatment. The escalating number of patent expiries is anticipated to propel the request for the induction of novel oncology biosimilars, thereby catalyzing the growth of the oncology biosimilars market._x000D_

_x000D_

#How Is the Oncology Biosimilars Market Segmented?#_x000D_

The oncology biosimilars market covered in this report is segmented –_x000D_

_x000D_

1) By Drug Type: Monoclonal Antibody, Immunomodulators, Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF)_x000D_

2) By Cancer Type: Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, Other Cancer Types_x000D_

3) By Distribution Type: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy_x000D_

_x000D_

Subsegments:_x000D_

1) By Monoclonal Antibody: Rituximab Biosimilars, Trastuzumab Biosimilars, Bevacizumab Biosimilars, Pembrolizumab Biosimilars_x000D_

2) By Immunomodulators: Thalidomide Biosimilars, Lenalidomide Biosimilars, Pomalidomide Biosimilars_x000D_

3) By Hematopoietic Agents: Epoetin Biosimilars, Darbepoetin Biosimilars_x000D_

4) By Granulocyte Colony-Stimulating Factor (G-CSF): Filgrastim Biosimilars, Pegfilgrastim Biosimilars_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=2821&type=smp_x000D_

_x000D_

#Which Regions Are Driving the Next Phase of the Oncology Biosimilars Market Growth?#_x000D_

The countries covered in the oncology biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada._x000D_

_x000D_

#What Key Trends Are Shaping the Future of the Oncology Biosimilars Market?#_x000D_

There is a growing trend among pharmaceutical firms to increase their investments in research and development to create novel oncology biosimilars. These companies are taking advantage of the growing biosimilar market’s potential by incorporating significant funding in their R&D procedures, helping facilitate the creation and production of new biosimilars. For instance, Biocon Biologics, a biopharmaceutical firm rooted in India, and Viatris Inc., a U.S.-based biosimilar manufacturer, jointly introduced Abevmy (bevacizumab), their third oncology biosimilar, into the Canadian market in May 2022. Abevmy is a biosimilar of Avastin (bevacizumab) – a product of Roche, which is a recombinant humanized monoclonal antibody acting on vascular endothelial growth factor (VEGF). Abevmy functions by blocking VEGF, inhibiting the development of new blood vessels that tumours require for growth._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report_x000D_

_x000D_

#How Is the Oncology Biosimilars Market Defined and What Are Its Core Parameters?#_x000D_

Oncology biosimilars refer to biologically similar drugs or medications that are physiologically comparable to biological cancer treatments. Infection risk is increased by decreased white blood cell counts, which can be treated as a side effect of cancer therapy._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2821_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 3156230293_x000D_

Asia +44 2071930708_x000D_

Europe +44 2071930708_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model